Indegene Limited, a leading Indian healthcare technology company, has acquired BioPharm Communications, a U.S.-based marketing services agency and part of Omnicom Health Group, in a deal valued at up to $106 million. The acquisition, executed through Indegene’s U.S. subsidiary ILSL Inc., is aimed at enhancing Indegene’s capabilities in AI-powered marketing and advertising technology for the global pharmaceutical sector.
Founded in 2005, BioPharm is recognized for its data-driven healthcare marketing solutions, serving 17 of the world’s top 25 biopharma companies. With a team of over 90 professionals, the agency reported revenues of $38.13 million in 2024. BioPharm specializes in precision marketing that integrates omnichannel strategies and end-to-end media journeys, helping pharmaceutical clients achieve more measurable and scalable outcomes.
The acquisition aligns with Indegene’s strategy to expand its commercialization portfolio by integrating advanced AI and digital advertising technologies. By combining BioPharm’s expertise with its own data and analytics capabilities, Indegene aims to provide pharmaceutical companies with more effective and efficient marketing solutions, particularly in navigating the complexities of modern healthcare commercialization.
Manish Gupta, Chairman and CEO of Indegene, stated that the acquisition reinforces the company’s position as a preferred technology-driven partner for the life sciences industry. He highlighted that the integration of BioPharm’s capabilities will enable Indegene to deliver greater strategic value from clients’ marketing and AdTech investments.
The deal is structured as an all-cash transaction with provisions for deferred, performance-based consideration. This strategic move emphasizes Indegene’s commitment to expanding its presence in the AI-driven marketing and advertising space, positioning the company as a key player in the evolving pharmaceutical marketing landscape.